@ScripMandy

I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.

 San Diego, CA
scrip.citeline.com
Joined May 2012
  • Tweets17.7K
  • Following747
  • Followers5.6K
360Media
Mandy Jackson retweeted
Renaissance Capital@IPOtweetOct 20
Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO $LYCA $IPO #IPO zpr.io/5mgVNLgN9d3G

Allergy and autoimmune biotech Lycia Therapeutics sets terms for $250 million IPO

Lycia Therapeutics, a Phase 1 biotech developing protein degraders for food allergy and Graves' disease, announced terms for its IPO on Tuesday.The South San Francisco, CA-based company plans to...

renaissancecapital.com
1
1
1,133
Mandy Jackson retweeted
Renaissance Capital@IPOtweetSep 25
siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range $ADRX $IPO #IPO zpr.io/PCejemsLJSwc

siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range

ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, raised $446 million by offering 26.3 million shares at $17, the high end of the $15 to $17 range.

renaissancecapital.com
2
3
2,578
Mandy Jackson retweeted
Renaissance Capital@IPOtweetSep 10
SPAC Allarity Acquisition files for a $100 million IPO, targeting life sciences and biotech $ALLNU $IPO #IPO zpr.io/wVzhE3BJbr8k

SPAC Allarity Acquisition files for a $100 million IPO, targeting life sciences and biotech

Allarity Acquisition, a blank check company backed by Allarity Therapeutics targeting life sciences and biotech, filed on Thursday with the SEC to raise up to $100 million in an initial public...

renaissancecapital.com
1
1
4
2,327
Mandy Jackson retweeted
Renaissance Capital@IPOtweetAug 6
Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range $BRVE $IPO #IPO zpr.io/vicRzHeAxzR4

Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range

Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, raised $383 million by offering 21.3 million shares at $18, above the $15 to $17 range.

renaissancecapital.com
1
1
1,203
Mandy Jackson retweeted
Renaissance Capital@IPOtweetAug 5
Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected $ATTO $IPO #IPO zpr.io/mvXbGPDhQBD2

Immune-focused biotech Attovia Therapeutics prices previously upsized IPO at $17, as expected

Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, raised $289 million by offering 17 million shares at $17, as expected.

renaissancecapital.com
1
2
1,436
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 29
Metabolic disorders biotech Vogenx sets terms for $75 million IPO $VOGX $IPO #IPO zpr.io/A9fsfXcJNdHJ

Metabolic disorders biotech Vogenx sets terms for $75 million IPO

Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, announced terms for its IPO on Wednesday.The Raleigh, NC-based company plans to raise $75 million by offering...

renaissancecapital.com
1
2
1,715
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 29
Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO $ATTO $IPO #IPO zpr.io/jyNnjBbUXVL8

Phase 1 immune system diseases biotech Attovia Therapeutics sets terms for $200 million IPO

Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, announced terms for its IPO on Wednesday.The San Carlos, CA-based company plans to raise $200 million...

renaissancecapital.com
1
3
1,495
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 27
Obstructive Sleep Apnea pharma Apnimed sets terms for $150 million IPO $APMD $IPO #IPO zpr.io/uZSJRczfJMDa

Obstructive Sleep Apnea pharma Apnimed sets terms for $150 million IPO

Apnimed, a late-stage drug developer advancing a pill for obstructive sleep apnea, announced terms for its IPO on Monday.The Cambridge, MA-based company plans to raise $150 million by offering 10...

renaissancecapital.com
1
3
1,310
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 17
Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO $LTGO $IPO #IPO zpr.io/bdDvEcRAbB2g

Acute and chronic pain relief biotech Latigo Biotherapeutics files for a $100 million IPO

Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, filed on Friday with the SEC to raise up to $100 million in an initial public...

renaissancecapital.com
1
1
3
1,978
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 17
Hypoxia-focused biotech NuvOx Therapeutics files for a $20 million IPO $NUOX $IPO #IPO zpr.io/nwkqHziYVPhZ

Hypoxia-focused biotech NuvOx Therapeutics files for a $20 million IPO

NuvOx Therapeutics, a Phase 2 biotech developing oxygen therapeutics to treat hypoxia, filed on Friday with the SEC to raise up to $20 million in an initial public offering.

renaissancecapital.com
1
2
1,551
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 17
Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO $BLSM $IPO #IPO zpr.io/XAQEe2NR5QLL

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO

BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.BlossomHill...

renaissancecapital.com
1
4
1,700
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 14
Phase 1 immune system diseases biotech Attovia Therapeutics files for a $100 million IPO $ATTO $IPO #IPO zpr.io/qtqJ7kGQ2imq

Phase 1 immune system diseases biotech Attovia Therapeutics files for a $100 million IPO

Attovia Therapeutics, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.Attovia...

renaissancecapital.com
1
1
1,467
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJul 15
Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO $BRVE $IPO #IPO zpr.io/nPZQidi4Fa32

Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO

Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.Braveh...

renaissancecapital.com
1
1
12,959
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJun 11
Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO $KARD $IPO #IPO zpr.io/vBA43UPS7v7D

Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO

Kardigan, a Phase 2b/3 biotech developing therapies for cardiovascular diseases, announced terms for its IPO on Thursday.The Princeton, NJ-based company plans to raise $350 million by offering 23.3...

renaissancecapital.com
1
1
916
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJun 9
Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO $PBLS $IPO #IPO zpr.io/J2ga66fivmGy

Cancer biotech Parabilis Medicines ups shares offered by 33% ahead of $600 million IPO

Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, raised the proposed deal size for its upcoming IPO on Tuesday.The Cambridge, MA-based company now...

renaissancecapital.com
1
1,008
Mandy Jackson retweeted
Renaissance Capital@IPOtweetJun 3
Cancer biotech Parabilis Medicines sets terms for $450 million IPO $PBLS $IPO #IPO zpr.io/Ye47Xm5jNqJr

Cancer biotech Parabilis Medicines sets terms for $450 million IPO

Parabilis Medicines, a clinical-stage biotech developing engineered peptide therapies for cancer, announced terms for its IPO on Wednesday.The Cambridge, MA-based company plans to raise $450 million...

renaissancecapital.com
2
3
1,031
Mandy Jackson retweeted
Sue Sutter@PinkSheetSutterJun 3
SCOOP: $AMGN Fights @US_FDA On Tavneos Withdrawal Over Efficacy, Data Integrity Concerns insights.citeline.com/pink-s…

Amgen Requests FDA Hearing To Keep Tavneos On The US Market

Amgen's request sets up a rare public fight over the forced withdrawal of a drug with regular approval. CDER wants the vasculitis drug Tavneos (avacopan) pulled over insufficient efficacy evidence...

insights.citeline.com
3
1
2
2,451
Mandy Jackson retweeted
Renaissance Capital@IPOtweetApr 27
Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week $COAG $IPO #IPO zpr.io/JXMKwzhBybyY

Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing...

Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, announced terms for its IPO on Monday.The Cambridge, MA-based company plans to raise $200...

renaissancecapital.com
1
8
1,299
Mandy Jackson retweeted
Renaissance Capital@IPOtweetApr 27
Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week $SPTX $IPO #IPO zpr.io/9GErFXwc3zNm

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this...

Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday.The Boston, MA-based company plans to raise $201 million by...

renaissancecapital.com
1
4
910
Mandy Jackson retweeted
Renaissance Capital@IPOtweetApr 23
Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO $AVLN $IPO #IPO zpr.io/wetkKAzb4sA5

Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO

Avalyn Pharma, a Phase 2 biotech developing inhaled medicines for rare respiratory diseases, announced terms for its IPO on Thursday.The Boston, MA-based company plans to raise $201 million by...

renaissancecapital.com
1
4
1,141
Load more